Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun;40(16_suppl):e19551.
Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Suppl 1):4956. doi: 10.1182/blood-2021-153190
Purser M, Gallagher M, Mladsi D, Weber JM, Andermariam B, Kaye JA, Chawla A. Development of key criteria for an economic model for a potentially curative one-time treatment for sickle cell disease and evaluation of published models with respect to these criteria. Hemasphere. 2020;p.1098-9.
Goyal R, Karve S, Nagar S, Kaye JA, Mato AR. Real-world treatment patterns and associated adverse events among patients with mantle cell lymphoma (MCL) in the United States. Blood. 2017 Dec;130(Suppl 1):5650. doi: 10.1182/blood.V130.Suppl_1.5650.5650
Davis KL, Gutierrez B, Zyczynski TM, Kaye JA. Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. J Clin Oncol. 2012 May 20;30(Suppl 15):e15165. doi: 10.1200/jco.2012.30.15_suppl.e15165
Yen L, Davis KL, Hodgkins P, Loftus EVJr, Erder MH. Direct medical costs of diverticulitis in a US managed care population. Am J Manag Care. 2012;4(5):e118-29.
Knoll S, Jochum D, Talbird S. Comparative cost benefit analysis of two new Pneumococcal Conjugate Vaccines (PHiD-CV and PCV-13). Klin Padiatr. 2010 Jun 1;222(Suppl 1):S51-2.
Smart JD, Nicholls TJ, Green KL, Rogers DJ, Cook JD, Wolowacz SE. Lectins in drug delivery: an in vivo toxicity study of the lectins from Solanum tuberosum and Helix pomatia. J Pharm Pharmacol. 1998 Sep.